Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by D'Ambrosio, R.
Right arrow Articles by Margaglione, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D'Ambrosio, R.
Right arrow Articles by Margaglione, M
Haematologica, Vol 89, Issue 12, 1510-1516
Copyright © 2004 by Ferrata Storti Foundation

Journal Article

Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin

RL D'Ambrosio, G D'Andrea, F Cappucci, M Chetta, P Di Perna, V Brancaccio, E Grandone, and M Margaglione

Istituto di Genetica Medica, Dipartimento di Scienze Biomediche, Universita di Foggia, Italy.

BACKGROUND AND OBJECTIVES: There is very considerable inter-individual variability in warfarin dosages necessary to achieve target therapeutic anticoagulation. The variability is largely genetically determined but can only partly be explained by genetic variability in the cytochrome CYP2C9 locus. Polymorphisms within the genes coding for vitamin K-dependent proteins have been suggested to predict sensitivity to warfarin therapy. DESIGN AND METHODS: In a cohort of 147 patients followed-up at one specialized clinic from the start of anticoagulation with warfarin, we investigated whether factor II (Thr165Met; G20210A) and factor VII polymorphisms (G-402A; G-401T) affected the doses of warfarin necessary to acquire the target intensity of anticoagulation. RESULTS: Regardless of the presence of confounding variables, the mean adjusted dose of warfarin required was higher among patients with the factor II Thr/Thr 165 genotype (4.2 mg) than among patients carrying the Met165 allele (2.9 mg; p=0.041) and higher in carriers of the factor VII GG-401 genotype (4.1 mg) than in those with the T-401 allele (3.1 mg; p=0.029). No significant effect was found for factor II A20210G and factor VII G-402A polymorphisms. All together, the genetic variants investigated accounted for about a quarter (r2: 0.261) of the inter-individual variability calculated in the present setting. INTERPRETATION AND CONCLUSIONS: Genetic variants of factor II and factor VII modulate the mean daily dose of warfarin required to achieve a target intensity of anticoagulation.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
E. Krynetskiy and P. McDonnell
Building Individualized Medicine: Prevention of Adverse Reactions to Warfarin Therapy
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 427 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
M. D. Caldwell, R. L. Berg, K. Q. Zhang, I. Glurich, J. R. Schmelzer, S. H. Yale, H. J. Vidaillet, and J. K. Burmester
Evaluation of Genetic Factors for Warfarin Dose Prediction
Clin. Med. Res., March 1, 2007; 5(1): 8 - 16.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. C. DeLozier, S.-C. Lee, S. J. Coulter, B. C. Goh, and J. A. Goldstein
Functional Characterization of Novel Allelic Variants of CYP2C9 Recently Discovered in Southeast Asians
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1085 - 1090.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.